169 related articles for article (PubMed ID: 34678509)
21. Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2.
Ge S; Lu J; Hou Y; Lv Y; Wang C; He H
Virology; 2021 Aug; 560():110-115. PubMed ID: 34052578
[TBL] [Abstract][Full Text] [Related]
22. Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing.
Luedemann M; Stadler D; Cheng CC; Protzer U; Knolle PA; Donakonda S
Comput Struct Biotechnol J; 2022; 20():799-811. PubMed ID: 35126884
[TBL] [Abstract][Full Text] [Related]
23. The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19.
Ahmad I; Pawara R; Surana S; Patel H
Top Curr Chem (Cham); 2021 Oct; 379(6):40. PubMed ID: 34623536
[TBL] [Abstract][Full Text] [Related]
24. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.
Padmanabhan P; Desikan R; Dixit NM
PLoS Comput Biol; 2020 Dec; 16(12):e1008461. PubMed ID: 33290397
[TBL] [Abstract][Full Text] [Related]
25. Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro.
Unal MA; Bitirim CV; Summak GY; Bereketoglu S; Cevher Zeytin I; Besbinar O; Gurcan C; Aydos D; Goksoy E; Kocakaya E; Eran Z; Murat M; Demir N; Aksoy Ozer ZB; Somers J; Demir E; Nazir H; Ozkan SA; Ozkul A; Azap A; Yilmazer A; Akcali KC
Can J Physiol Pharmacol; 2021 May; 99(5):449-460. PubMed ID: 33689451
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.
Rangel HR; Ortega JT; Maksoud S; Pujol FH; Serrano ML
Virus Res; 2020 Nov; 289():198154. PubMed ID: 32918944
[TBL] [Abstract][Full Text] [Related]
27. Antiviral Activity of Two Marine Carotenoids against SARS-CoV-2 Virus Entry In Silico and In Vitro.
Yim SK; Kim I; Warren B; Kim J; Jung K; Ku B
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204256
[TBL] [Abstract][Full Text] [Related]
28. A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection.
Chen F; Shi Q; Pei F; Vogt A; Porritt RA; Garcia G; Gomez AC; Cheng MH; Schurdak ME; Liu B; Chan SY; Arumugaswami V; Stern AM; Taylor DL; Arditi M; Bahar I
Mol Syst Biol; 2021 Aug; 17(8):e10239. PubMed ID: 34339582
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Cells; 2021 Jun; 10(6):. PubMed ID: 34201214
[TBL] [Abstract][Full Text] [Related]
30. Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2).
Egieyeh S; Egieyeh E; Malan S; Christofells A; Fielding B
PLoS One; 2021; 16(1):e0245258. PubMed ID: 33417604
[TBL] [Abstract][Full Text] [Related]
31. Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
Dey M; Singh RK
Pharmacology; 2021; 106(9-10):469-476. PubMed ID: 34350893
[TBL] [Abstract][Full Text] [Related]
32. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
33. Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity.
Diomede L; Baroni S; De Luigi A; Piotti A; Lucchetti J; Fracasso C; Russo L; Bonaldo V; Panini N; Filippini F; Fiordaliso F; Corbelli A; Beeg M; Pizzato M; Caccuri F; Gobbi M; Biasini E; Caruso A; Salmona M
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578326
[TBL] [Abstract][Full Text] [Related]
34. Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2/CMC-HPLC-IT-TOF-MS approach.
Lv Y; Wang S; Liang P; Wang Y; Zhang X; Jia Q; Fu J; Han S; He L
Anal Bioanal Chem; 2021 May; 413(11):2995-3004. PubMed ID: 33608752
[TBL] [Abstract][Full Text] [Related]
35. Host Cell and SARS-CoV-2-Associated Molecular Structures and Factors as Potential Therapeutic Targets.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Roshan R; Azam F; Mehta J; Handu S; Prasad R; Jain N; Pandey AK; Dhamija P
Cells; 2021 Sep; 10(9):. PubMed ID: 34572076
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2.
Shajahan A; Archer-Hartmann S; Supekar NT; Gleinich AS; Heiss C; Azadi P
Glycobiology; 2021 May; 31(4):410-424. PubMed ID: 33135055
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanism of anti-SARS-CoV2 activity of Ashwagandha-derived withanolides.
Dhanjal JK; Kumar V; Garg S; Subramani C; Agarwal S; Wang J; Zhang H; Kaul A; Kalra RS; Kaul SC; Vrati S; Sundar D; Wadhwa R
Int J Biol Macromol; 2021 Aug; 184():297-312. PubMed ID: 34118289
[TBL] [Abstract][Full Text] [Related]
38. Population-Specific
Hashizume M; Gonzalez G; Ono C; Takashima A; Iwasaki M
Viruses; 2021 Jan; 13(1):. PubMed ID: 33418950
[TBL] [Abstract][Full Text] [Related]
39. Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis.
Hou Y; Ge S; Li X; Wang C; He H; He L
Chem Biol Interact; 2021 Apr; 338():109420. PubMed ID: 33609497
[TBL] [Abstract][Full Text] [Related]
40. Inhalable nanocatchers for SARS-CoV-2 inhibition.
Zhang H; Zhu W; Jin Q; Pan F; Zhu J; Liu Y; Chen L; Shen J; Yang Y; Chen Q; Liu Z
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34292870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
